Chemours Company (The) (CC) Upgraded to Buy at BidaskClub

BidaskClub upgraded shares of Chemours Company (The) (NYSE:CC) from a hold rating to a buy rating in a report issued on Wednesday, July 12th.

A number of other analysts also recently weighed in on CC. Jefferies Group LLC raised shares of Chemours Company (The) from a hold rating to a buy rating and raised their price target for the stock from $35.00 to $48.00 in a research report on Wednesday, March 29th. Citigroup Inc. reissued a neutral rating and set a $40.00 price target (up previously from $34.00) on shares of Chemours Company (The) in a research report on Friday, April 14th. J P Morgan Chase & Co raised shares of Chemours Company (The) from a neutral rating to an overweight rating and raised their price target for the stock from $39.00 to $50.00 in a research report on Friday, May 12th. Susquehanna Bancshares Inc raised their price objective on Chemours Company (The) from $45.00 to $55.00 and gave the stock a positive rating in a research note on Monday, May 15th. Finally, ValuEngine upgraded Chemours Company (The) from a hold rating to a buy rating in a research note on Friday, June 2nd. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of Buy and an average target price of $46.25.

Chemours Company (NYSE CC) traded down 5.16% during mid-day trading on Wednesday, hitting $47.20. 3,850,147 shares of the stock were exchanged. The stock has a market cap of $8.73 billion, a PE ratio of 30.87 and a beta of 3.63. Chemours Company has a 52-week low of $8.86 and a 52-week high of $50.04. The stock’s 50 day moving average is $41.37 and its 200 day moving average is $37.03.

Chemours Company (The) (NYSE:CC) last issued its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The company had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the company earned $0.27 earnings per share. Chemours Company (The)’s revenue for the quarter was up 14.8% on a year-over-year basis. Analysts forecast that Chemours Company will post $3.51 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Chemours Company (The) (CC) Upgraded to Buy at BidaskClub” was first published by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.themarketsdaily.com/2017/08/08/chemours-company-the-cc-stock-rating-upgraded-by-bidaskclub-updated-updated-updated.html.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 17th will be issued a dividend of $0.03 per share. This represents a $0.12 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date is Tuesday, August 15th. Chemours Company (The)’s payout ratio is currently 8.11%.

In other Chemours Company (The) news, VP Erich Parker sold 4,908 shares of the firm’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $45.53, for a total transaction of $223,461.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul Kirsch sold 19,036 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $41.42, for a total value of $788,471.12. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

A number of large investors have recently bought and sold shares of CC. Nationwide Fund Advisors raised its stake in Chemours Company (The) by 262.6% in the first quarter. Nationwide Fund Advisors now owns 413,027 shares of the specialty chemicals company’s stock valued at $15,902,000 after buying an additional 299,121 shares during the period. Ameritas Investment Partners Inc. raised its stake in Chemours Company (The) by 349.0% in the first quarter. Ameritas Investment Partners Inc. now owns 69,460 shares of the specialty chemicals company’s stock valued at $2,674,000 after buying an additional 53,991 shares during the period. Pacer Advisors Inc. bought a new stake in Chemours Company (The) during the first quarter valued at $917,000. Dynamic Technology Lab Private Ltd raised its stake in Chemours Company (The) by 60.5% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,325 shares of the specialty chemicals company’s stock valued at $974,000 after buying an additional 9,549 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Chemours Company (The) by 51.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 491,439 shares of the specialty chemicals company’s stock valued at $10,856,000 after buying an additional 167,183 shares during the period. Hedge funds and other institutional investors own 75.21% of the company’s stock.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply